glp-1 medication Medications: Everything You Need to Know Comparing Ozempic, Wegovy and Other
Description
Feel lighter and more in control of your life
Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the therapeutic landscape of type 2 diabetes (T2D) and obesity by offering substantial weight loss and cardiometabolic protection
2026: Acceleration and Market Transformation The coming year promises rapid evolution across innovation, policy, and market access
